This HTML5 document contains 90 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00411/identifier/chebi/
n27http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00411/identifier/pharmgkb/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00411/identifier/wikipedia/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00411/identifier/pdb/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00411/identifier/kegg-drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00411/identifier/drugbank/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00411/identifier/iuphar/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00411/identifier/guide-to-pharmacology/
n3http://linked.opendata.cz/ontology/drugbank/
n11http://www.drugs.com/cdi/
n10http://www.rxlist.com/cgi/generic2/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00411/identifier/national-drug-code-directory/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00411
rdf:type
n3:Drug
n3:description
A slowly hydrolyzed cholinergic agonist that acts at both muscarinic and nicotinic receptors. [PubChem]
n3:dosage
n8:271B465D-363D-11E5-9242-09173F13E4C5 n8:271B465E-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
Primarily used in the treatment of glaucoma, but is also used during ophthalmic surgery.
n3:manufacturer
n12:271B4653-363D-11E5-9242-09173F13E4C5 n12:271B4651-363D-11E5-9242-09173F13E4C5 n12:271B4652-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00411 n20:DB00411
dcterms:title
Carbachol
adms:identifier
n14:298 n15:D00524 n16:298 n17:3385 n18:DB00411 n19:Carbachol n24:PA448784 n25:58768-735-12 n26:CCE
n3:mechanismOfAction
Carbachol is a parasympathomimetic that stimulates both muscarinic and nicotinic receptors. In topical ocular and intraocular administration its principal effects are miosis and increased aqueous humour outflow.
n3:packager
n12:271B464F-363D-11E5-9242-09173F13E4C5 n12:271B4650-363D-11E5-9242-09173F13E4C5 n12:271B464D-363D-11E5-9242-09173F13E4C5 n12:271B464E-363D-11E5-9242-09173F13E4C5 n12:271B464C-363D-11E5-9242-09173F13E4C5
n3:synonym
Carbacol Karbachol Carbacholum Karbamoylcholin chlorid 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminium chloride (2-Hydroxyethyl)trimethylammonium chloride carbamate Carbachol chloride Choline chlorine carbamate (2-Hydroxyethyl)trimethyl ammonium chloride carbamate 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminum chloride Choline chloride, carbamate Carbamylcholine Choline carbamate chloride (2-Carbamoyloxyethyl)trimethylammonium chloride
n3:toxicity
Oral, mouse: LD<sub>50</sub> = 15 mg/kg; Oral, rat: LD<sub>50</sub> = 40 mg/kg.
n21:hasAHFSCode
n27:52-20-00 n27:12-04-00
n3:synthesisReference
Major, R.T. and Bonnett, H.T.; U.S. Patent 2,374,367; April 24,1945; assigned to Merck & Co., Inc.
foaf:page
n10:carbachol.htm n11:carbachol-drops.html
n3:IUPAC-Name
n4:271B4663-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4669-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4668-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4665-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4666-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4667-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4661-363D-11E5-9242-09173F13E4C5 n4:271B4678-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B465F-363D-11E5-9242-09173F13E4C5 n4:271B4662-363D-11E5-9242-09173F13E4C5 n4:271B467A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4660-363D-11E5-9242-09173F13E4C5
n21:hasATCCode
n22:N07AB01 n22:S01EB02
n3:H-Bond-Acceptor-Count
n4:271B466F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4670-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B466A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B466B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B466D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B466C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B466E-363D-11E5-9242-09173F13E4C5
n3:absorption
Not well absorbed in the gastro-intestinal tract, and does not cross the blood-brain barrier.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
51-83-2
n3:category
n3:containedIn
n5:271B4655-363D-11E5-9242-09173F13E4C5 n5:271B4658-363D-11E5-9242-09173F13E4C5 n5:271B4659-363D-11E5-9242-09173F13E4C5 n5:271B4656-363D-11E5-9242-09173F13E4C5 n5:271B4657-363D-11E5-9242-09173F13E4C5 n5:271B465C-363D-11E5-9242-09173F13E4C5 n5:271B465A-363D-11E5-9242-09173F13E4C5 n5:271B465B-363D-11E5-9242-09173F13E4C5 n5:271B4654-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4674-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4676-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4677-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4679-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4673-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4672-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4675-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4664-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4671-363D-11E5-9242-09173F13E4C5